Fibrates in CVD: a step towards personalised medicine (Q43050781)

13 November 2017

Fibrates in CVD: a step towards personalised medicine (English)

1 reference

13 November 2017

1

1 reference

PubMed ID

20510999

13 November 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

13 November 2017

1 reference

13 November 2017

375

1 reference

13 November 2017

9729

1 reference

13 November 2017

1847-1848

1 reference

Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced?

13 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Fibrates, glitazones, and peroxisome proliferator-activated receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Effects of combination lipid therapy in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

Safety considerations with fibrate therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2810%2960758-1

7 January 2021

10.1016/S0140-6736(10)60758-1

Identifiers

DOI

1 reference

13 November 2017

1 reference

PubMed ID

20510999